Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Rare Malignant Solid Neoplasm”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Not applicableLooking for participantsNCT03739827
What this trial is testing

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Who this might be right for
Malignant Solid TumorsOther Neoplasms Solid TumorsPediatric Solid Tumor+2 more
National Cancer Institute (NCI) 10,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT02867592
What this trial is testing

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Who this might be right for
Adrenal Cortical CarcinomaAlveolar Soft Part SarcomaCentral Nervous System Neoplasm+41 more
National Cancer Institute (NCI) 109
Testing effectiveness (Phase 2)Active Not RecruitingNCT05715281
What this trial is testing

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Who this might be right for
Advanced Rare Malignant Solid NeoplasmRare Malignant Solid NeoplasmRefractory Rare Malignant Solid Neoplasm
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167
What this trial is testing

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Early research (Phase 1)Active Not RecruitingNCT03478462
What this trial is testing

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Who this might be right for
Pediatric Solid TumorPediatric LymphomaPediatric Brain Tumor+5 more
Cellectar Biosciences, Inc. 30